Eczema the hidden face of primary immunodeficiency diseases by Radwan, Nesrine
Egypt J Pediatr Allergy Immunol 2019; 17(1):3-11. 
3 
 
Eczema the hidden face of primary immunodeficiency diseases 
 
Nesrine Radwan 
Lecturer of Pediatrics 
Pediatric Allergy and Immunology Unit, Children’s Hospital, Ain Shams University, Cairo, Egypt 
 
Primary immunodeficiency diseases (PIDs) are a 
group of more than 130 disorders caused by genetic 
defects of the immune system. Most of these 
disorders are caused by single gene defects, but the 
variable penetrance of these mutations results in 
heterogeneous phenotypes which lead to a delay in 
the diagnosis.1 In the USA, the prevalence of all 
PIDs per 100,000 has increased over the last decade 
from 66.6 in 2003 to 126.8 in 20122 and this could 
reflect the rise in the disease awareness. The 
classical clinical presentation of PIDs includes 
recurrent or unusual infections, however, new 
presentations are now coming to attention such as 
autoimmune diseases, malignancy and cutaneous 
manifestations.3   
Cutaneous manifestation in PIDs affects around 
40 % to 70 % of patients and they include various 
presentation as eczema, cutaneous granulomas, 
recurrent abscesses, dysplasia of skin, hair, and 
nails, autoimmune conditions, and others.4 Dhouib 
et al found that the incidence of cutaneous 
manifestation among 200 children with PIDs to be 
56%5, whereas Al-Herz6 et al and Moin et al7 found 
it to be 48% and 32% respectively. Cutaneous 
manifestations could be the first presenting 
symptoms and faulty presenting to dermatologist. In 
a series of 75 patients with severe dermatitis with 
no known underlying primary immunodeficiency, 
Aghamohammadi et al identified 5 patients with 
hyperimmunoglobulin E syndrome (HIES) and one 
patient with Wiskott Aldreich syndrome (WAS).8 
This raises the awareness to suspect an underlying 
PID in patients presenting with severe and non-
resolving cutaneous manifestation. 
Eczema (Atopic dermatitis “AD”) is an 
inflammatory, chronically relapsing, non-
contagious and extremely pruritic skin disease.9 It is 
commonly associated with an elevation in total 
immunoglobulin E, which sometimes correlates 
with disease severity.10,11 The prevalence of 
childhood AD ranges from 15% to 30%. AD is one 
of the commonest cutaneous manifestations for 
some PID diseases12 and sometime used as one of 
the disease diagnostic critieria13 of HIES, WAS, and 
others (Table). It is characterized by being severe, 
resistant to treatment and associated by chronic or 
recurrent viral or bacterial infections.14 Such 
condition confirms the importance of eliciting 
history of recurrent infections in affected patients or 
history of infection in any of their family members .
  
Table 1. Primary immunodeficiency diseases 




Selective IgM deficiencyb 
X-linked agammaglobulinemiab 
X-linked immunodeficiency with hyper-IgMb  
Ataxia telangiectasia 
Selective IgA deficiencya 
Severe combined immunodeficiency  
Primary neutropenia 
Schwachman Diamond syndromeb  
Chronic granulomatous diseaseb 
a Associated with atopic eczema 
b Occasional association with atopic eczema claimed in some 
reports 
 
Hyper-IgE syndrome (HIES) 
The first HIES was described in 1996 (Job’s 
syndrome). The syndrome includes a combination 
of recurrent cold abscesses, eczematous dermatitis 
and lung disease and elevated IgE>2000 IU/ µL.16 It 
is also known as autosomal dominant HIES (AD-
HIES). It shares several clinical features with 
dedicator of cytokinesis 8 (DOCK8) deficiency, 
known as autosomal recessive (AR)-HIES. In 
addition, there are two other rare autosomal 
recessive diseases associated with HIES. The first is 
caused by mutations in phosphoglucomutase-3 
(PGM3) and the second is associated with a 
mutation in tyrosine kinase 2 (Tyk2). Both could 
also share some features with AD-HIES.14 
 
AD-HIES 
AD-HIES was found to be caused by a mutation in 
the signal transducer and activator of transcription 3 
(STAT3).17,18 STAT3 is important in wound 
healing, angiogenesis, cancer and immune 




cell differentiation and interleukin 17 (IL-17) 
production.21,22 Th17 is needed for neutrophil 
recruitment23 and defense against Staphylococcus 
aureus infection which is considered the main 
infectious pathogens present in such patients.19  
Accordingly, patients usually present in the 
neonatal period with papulopustular eruption that 
changes into eczema24, recurrent sinopulmonary 
infections ending into abscess formation and 
pneumatocele which predispose patients to 
subsequent Pseudomonas, Aspergillus, or atypical 
mycobacterial infections and additional morbidity.14  
Eczema in AD-HIES which starts at the neonatal 
period in 78% of cases. It usually begins as pink to 
red papules that become pustules, exude pus, and 
turn into a crusted form. Lichenification, xerosis 
and scales are either absent or mild. The rash is 
distributed on the scalp, face, neck, axillae, and 
diaper area. In older cases, eczema is seen in 100% 
of HIES patients and it is usually moderate to 
severe eczema in 71% of cases. The main clinical 
clues that differentiate it from atopic dermatitis 
include; a severe prolonged clinical course, 
beginning at an earlier age, atypical distribution on 
axillae, groin and perineum, chronicity of 
dermatitis, recurrent staphylococcal skin infections, 
cold abscesses and resistance to conventional 
therapy, and responsiveness to anti-staphylococcal 
antibiotics.16,25 
AD-HIES is a multisystem disease that also 
affects the connective tissue causing various 
skeletal and vascular disorders.23,26 Somatic features 
include facial asymmetry broad nose, high arched 
palate and porous skin. Skeletal manifestation 
includes osteopenia, increase liability of fracture to 
minimal trauma and hyperextensibility of joints. 
Vascular abnormalities may include coronary 
aneurysm and lacunar brain infarction.23,26 AD-
HIES is also associated with an increased risk of 
malignancy, most commonly non-Hodgkin’s 
lymphoma.27 The life expectancy of patients ranges 
from the fifth to the sixth decade. Mortality is most 
commonly from infection.28 The National Institute 
of Health (NIH) scoring system was developed for 
diagnosis due to phenotype variability. It uses both 
clinical and laboratory findings such as eczema, 
presence of facies, retained primary, serum IgE 
level and others. A total-point score of 15 points, 
makes the subject likely to carry an HIES genotype; 
at 10–14 points, the presence of an HIES genotype 
is indeterminate; and at <10 points, the subject is 
unlikely to have an HIES genotype.29 Treatment is 
supportive during infections and in between 
prophylactic treatment against Staphylococcal 
aureus using topical and systemic antiseptic.19 
Hematopoietic stem cell transplantation (HSCT) 




DOCK8 deficiency  
DOCK8 deficiency is an AR-HIES, first described 
in 2009.14 DOCK8 protein is normally expressed in 
mature peripheral T cells, hematopoietic stem cells, 
and thymocytes31. This protein mediates the 
cytoskeleton reorganization needed for 
hematopoietic stem cell homing and mobilization as 
well as T-cell polarization.32,33 DOCK8 deficiency 
is characterized by elevation of IgE, recurrent 
sinopulmonary infections, severe eczema with on 
top resistant staphylococcal aureus infection and 
finally multiple food allergies similar to AD-HIES. 
But unlike AD-HIES, it has increase liability to 
viral infection on top of eczema commonly by 
human papilloma virus and herpes virus14 that 
could lead to disfiguring scars and may predispose 
to malignancy. This could be due to associated 
impaired natural killer (NK) cell development and 
survival, which likely contributes to the profound 
susceptibility to cutaneous viral infections.34 Early 
bronchiectasis occurs in life.35 It has a higher 
mortality rate due to sepsis and higher risk of 
malignancy in the second and third decade of 
life.36 The diagnosis is somehow difficult due to 
the wide range of clinical phenotype.36  
Laboratory findings includes low numbers of or 
dysfunctional B cells and NK cells35,36 along with 
low CD4+ cells and CD8+ cells37 and low T cell 
receptor excision circles (TRECs).36,38 Some studies 
reported low IgM level.32 Treatment of eczema is 
difficult due to concomitant viral and bacterial 
infection.14 Patients with extensive viral skin 
infection should be treated with systemic antiviral 
as acyclovir or valacyclovir. Giving the risk of 
malignancy, HSCT represents a promising 
therapeutic option for DOCK8-deficient patients32 
as it ameliorates the infectious and atopic symptoms 
within the first 6 months.14 
 
PGM3 deficiency 
It is an autosomal recessive disease first described 
in 2014.39 PGM3 is a critical component of 
glycosylation pathway as it catalyzes the 
conversion of N-acetlyglucosamine-6-phosphate 
(GlcNAc-6-P) into GlcNAc-1-P in the synthesis of 
uridine diphosphate (UDP)-GlcNAc, thereby 
affecting a wide range of diverse proteins.40 It is 
considered to be a variant of HIES where patients 
usually present with atopic dermatitis, asthma and 
other allergies, in addition to recurrent 
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sinopulmonary infections ending with 
bronchiectasis, skin and soft tissue bacterial 
infections. In contrast to HIES patients presents 
with various neurological symptoms such 
developmental delay, ataxia, sensorineural hearing 
loss and abnormal EEG findings. Uniquely, it was 
found that numerous patients have leukocytoclastic 
vasculitis and hematologic manifestations such as 
cytopenia, namely lymphopenia and neutropenia.40 
 
Immune dysregulation, polyendocrinopathy and 
enteropathy, X-linked syndrome (IPEX)  
IPEX is an X-linked disease that is generally 
considered as a syndrome of neonatal 
enteropathy41,42 and polyendocrinopathy.41,43 It is 
due a mutation in FOXP3 gene44 which causes a 
decrease or absence in CD4+CD25+Treg cells and 
eventually loss of self-tolerance.43 There is a 
considerable variation in the clinical phenotype, but 
the awareness of the disease allowed picking 
atypical cases.44 The typical presentation usually 
starts in the first year of life with a triad of watery 
diarrhea, eczematoid dermatitis and type 1 diabetes 
mellitus45, which is considered the most common 
and early manifestation of endocrinopathy, 
followed by thyroiditis.41 There are other 
autoimmune manifestations as autoimmune 
cytopenia, hepatitis and nephritis. Alopecia has 
been reported in some cases.46 More than 50% of 
patients suffer from invasive sepsis, meningitis, 
osteomyelitis.47 Carrier females are generally 
healthy.45 Most patients have normal level of 
CD3+CD4+ and CD8+T-cells, with normal 
proliferative assay to mitogens. However, there is 
depletion of naïve T cell and increase in memory 
Tcell.48 Symptomatic treatment includes transfusion 
of necessary blood elements, immunosuppressive 
drugs and total parental nutrition.44 The only 
definitive cure is bone marrow transplantation 49, 
however, it will not cure the endocrinological 
disorders44,50 and the results in some studies were 
not permanent.51 




Omenn syndrome is an autosomal recessive disease 
of combined immunodeficiency52,53 and was first 
reported in 1985.54  It usually presents in early 
infancy with recurrent severe and serious infections 
as severe combined immunodeficiency (SCID), 
generalized rash usually exfoliative erythroderma, 
chronic diarrhea, generalized lymphadenopathy, 
hepatosplenomegaly and failure to thrive.14,55 The 
main pathology underlying its clinical picture is 
impairment of V(D)J recombination55 leading to 
abnormally expanded activated oligoclonal T 
lymphocytes predominantly Th2 type which will 
infiltrate the skin and gastrointestinal tract.52  Such 
abnormal T cells, working unopposed by other 
components of the immune system, will secrete 
cytokines promoting autoimmune and allergic 
inflammation.56 It results from hypomorphic 
mutations of genes associated with SCID which 
includes RAG1/2, Artemis, IL-7Rα, DNA ligase 
IV, RNA-processing endoribonuclease, ADA, and 
γc.57 In addition, it was found that some patients 
with atypical DiGeorge syndrome may present with 
a clinical phenotype resembling Omenn 
syndrome.58 A similar clinical picture occurs in 
SCID with materofetal engraftment indicating 
molecular genetic studies to differentiate the origin 
of the abnormal Tcell.59 Laboratory finding includes 
an elevation of serum IgE along with eosinophilia, 
despite having low or absent circulating B 
lymphocytes, decreased IgG, IgM, and IgA.59 T 
lymphocytes are normal or increased. Treatment is 
usually supportive in the form of immunoglobulin 
replacement therapy, prophylactic antimicrobials, 
and in some cases systemic immunosuppression till 
doing HSCT. Early HSCT is important as the 
disease is fetal.59 
 
Wiskott -Aldrich syndrome (WAS) 
WAS is an X-linked life threatening PID presenting 
with a triad of eczema and recurrent serious 
infections, micro-thrombocytopenia and is 
associated with high incidence of autoimmune 
diseases and malignancy.60 Its incidence is one to 
four cases per 1,000,000 live male births, with an 
average age at diagnosis of 24 months in families 
without a previously affected family member.61 
WAS is due to a defect in the WAS protein 
(WASP), which is a member of a family of proteins 
involved in signaling and actin cytoskeletal 
organization.62 Actin cytoskeleton is important for 
vital cells function as growth, endocytosis, 
exocytosis and cytokinesesis.63 Accordingly, 
mutation in this protein will affect the proper 
signaling and growth of different haemopoietic 
lineage and abnormal migration64 and motility of 
many immune cellular components especially 
dendritic cells, myeloid cells ,macrophages ,natural 
killers and T and B cells.65,66 The responsible gene 
was identified in 1994 and since then clinical and 
basic researches has started67 which lead to more 
understanding of the protein function and its 
expression and its correlation with different clinical 
and phenotypic spectrum . 
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The other two different phenotypes are the X-
linked thrombocytopenia (XLT) and X-linked 
neutropenia (XLN).68 Reversion to normal of 
inherited mutation had been reported in some cases 
of WAS leading to a somatic mosaicism and mild 
clinical phenotype. Classical WAS usually presents 
early in life with the triad. The most common 
organisms are Pneumocystis jirovecii, HSV and 
varicella, and invasive fungal infections.56 
Thrombocytopenia causes bleeding tendency with 
variable severity and sometimes misdiagnosed as 
ITP due to presence anti-platelet antibody.66 
Eczema develops in 80% of WAS patients69 and 
varies in its severity and response to the standard 
therapy. It has no distinct features from atopic 
dermatitis.  Autoimmune manifestations occur in 
40-70% of patients60 and usually presents in the 
first two years of life.70 It is due to the defect in the 
peripheral tolerance due to defective T regulatory 
cells (Tregs) due to abnormal WASP.71 Malignancy 
occurs in 10-20% of patients and mainly it is 
lymphoreticular as lymphoma.69  
A scoring system is used to define the variable 
phenotype of WAS (0-5) and to predict patients’ 
prognosis. The clinical scoring system is derived 
from a variety of clinical parameters, including the 
presence of thrombocytopenia, eczema, 
immunodeficiency, autoimmunity, and malignancy.  
A WAS score greater than or equal to 3 is 
considered “classic” WAS. These patients have 
thrombocytopenia, eczema, immunodeficiency, and 
infectious. The presence of autoimmunity and/or 
malignancy is consistent with a WAS score of 5. 
Transient eczema, immunodeficiency, and mild 
infectious complications may also occur and may 
not portend a bad prognosis. These patients may be 
classified as XLT and will have a WAS score of 2. 
A WAS score of 0 is reserved for those patients 
with gain-of-function mutations associated with 
XLN and/or myelodysplasia. Patients may change 
from a lower WAS score to a higher WAS 
score.72,73,74 
The characteristic laboratory finding is micro-
thrombocytopenia and eosinophilia in the peripheral 
blood. Serum immunoglobulin levels show low 
IgM, high IgE and variable IgA and IgG. Flow 
cytometry reveals mild T cell lymphopenia, normal 
B cell, and normal or increased NK cells.  The 
evaluation of  WASP expression is important for 
diagnosis.75 Poor response to polysaccharide 
vaccine are noted along with poor lymphocyte 
proliferation and NK cytotoxicity.75 Treatment of 
WAS patients includes supportive treatment for 
active infections and autoimmune diseases and 
prophylactic antibiotics to guard against infection. 
The curative treatment is achieved by HSCT with 
better results if done at younger age.61 The new 
recommended treatment now is gene therapy which 
was found to cause improvement at 24 months in 
eczema, the frequency and severity of infections, 
bleeding tendency, autoimmunity, reduction in 
disease-related days of hospitalization, and 
improvement in immunological and hematological 
parameters.76  
 
Other PIDs rarely present with eczema 
Selective IgA deficiency  
Selective IgA deficiency is the most common PID 
syndrome in humans. It is more common in females 
than males. Symptoms usually includes recurrent, 
sometimes severe infections, particularly of the 
upper and lower respiratory and gastrointestinal 
tract. The most common offending pathogens are 
Gram-positive cocci, H. influenzae, and E. coli. 
Giardiasis, celiac disease, and malignancies have 
been described. There is an increased incidence of 
autoimmune diseases and lymphoreticular 
neoplasms.77 A major feature of selective IgA-
deficiency is the high incidence of atopic diseases. 
In a large series of IgA-deficient children, Plebani 
et al. found clinical manifestations of atopic 
symptoms in 25 % of patients. Atopic 
manifestations included allergic rhinitis, asthma, 
urticaria, and AD. Eczema was much less 
frequently found than rhinitis and asthma. 
Association with atopic symptoms was clearly 
linked to the presence of elevated IgE in more than 
50 % of patients.78 The underlying pathogenesis is 
attributed to failure of B cells to differentiate into 
IgA-secreting plasma cells. Severe and partial 
forms of the disease are distinguished, the former 
being defined as IgA levels below 7 mg/dl plus 
absence of secretory IgA. IgG and IgM as well as 
specific antibody production following 
immunization are usually normal, but IgG 
subclasses (IgG2, IgG4) may be deficient.77 
Moreover, serum IgE is elevated in 30 %, as are 
eosinophils. B and T lymphocytes are normal in 
number and function. IgA B cells, however, are 
arrested at an early stage of maturation and fail to 
differentiate further.78 Although no consistent T cell 
defect has been demonstrated, subtly defective 
immunoregulation by T cells appears to be a major 
pathogenic feature.79 
 
Selective IgM deficiency  
Selective IgM deficiency is another very rare PID 
syndrome found in some patients with autoimmune 
diseases, characterized by the partial absence of 
IgM while the levels of other immunoglobulins are 
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normal. It is likely to be an X-linked disorder, its 
pathogenesis and relationship with autoimmunity 
remain unclear. Reduction or absence of secreted 
IgM may correlate with the progression of 
autoimmune diseases in humans.80 In milder forms 
of IgM deficiency, recurrent Gram- positive 
infections predominate; severe deficiency often 
leads to fatal meningococcal septicemia and may be 
associated with AD according to some reports.15  
 
Mammalian sterile 20-like 1(MST-1) 
Mammalian sterile 20-like 1(MST-1) deficiency, 
also known as serine/threonine protein kinase 4 
(STK4) deficiency, is an autosomal recessive 
disorder characterized by recurrent bacterial, viral 
and candida cutaneous infection along with 
structural cardiac anomalies. It rarely presents with 
eczema.14 but is usually associated with bacterial 
and viral infections (HSV, HPV, MCV, EBV) as 
well as mucocutaneous candidiasis.  The disease 
was first reported in 2012, when four 
consanguineous affected families with MST-1 
deficiency have been described.81,82 Systemic 
findings include structural cardiac anomalies (atrial 
septal defects and patent foramen ovale) and 
valvular disease.83 Eczematous dermatitis has been 
reported, but is poorly characterized.83 Affected 
patients have a peripheral neutropenia with normal 
bone marrow maturation, as well as T and B cell 
lymphopenia. The primary therapeutic intervention 
for this condition is infection control. Three patients 
with MST-1 deficiency have undergone HSCT, but 
two died within six months due to graft-versus-host 
disease and infectious complications.14 
 
Shwachman- Diamond syndrome 
Shwachman-Diamond syndrome is an autosomal 
recessive multisystem disorder involving an 
insufficiency of the exocrine pancreas and 
hematological problems as main symptoms. 
Frequently, ichthyosiform skin lesions are 
described but are usually not the leading symptom 
of the disease. It may present with skin eruptions as 
main symptom. A mixed clinical picture with an 
atopic dermatitis may occur and can aggravate skin 
symptoms. Additional medical problems like failure 
to thrive or neutropenia should lead to further 




Dermatological disorders should be considered as 
one of the main clinical manifestation of PID 
especially eczema. It might be the first and only 
presenting symptoms. Eczema in early age is an 
alerting sign. Eczema resistant to treatment, 
recurrent and/or in unusual sites is another altering 
sign. Accordingly, dermatologist should be vigilant 
to suspect PID in any case presenting with recurrent 
and/or persistent skin diseases. 
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